{"nctId":"NCT00855335","briefTitle":"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","startDateStruct":{"date":"2009-04-09","type":"ACTUAL"},"conditions":["HIV","HIV Infections","Pregnancy"],"count":77,"armGroups":[{"label":"Group 1: Darunavir 600 /Ritonavir 100","type":"EXPERIMENTAL","interventionNames":["Drug: Darunavir","Drug: Ritonavir"]},{"label":"Group 2: Darunavir 800/Ritonavir 100","type":"EXPERIMENTAL","interventionNames":["Drug: Darunavir","Drug: Ritonavir"]},{"label":"Group 3: Etravirine","type":"EXPERIMENTAL","interventionNames":["Drug: Etravirine"]},{"label":"Group 4: Rilpivirine","type":"EXPERIMENTAL","interventionNames":["Drug: Rilpivirine"]},{"label":"Group 5: Darunavir 800/Cobicistat 150","type":"EXPERIMENTAL","interventionNames":["Drug: Darunavir/Cobicistat (FDC)"]}],"interventions":[{"name":"Darunavir","otherNames":[]},{"name":"Ritonavir","otherNames":[]},{"name":"Etravirine","otherNames":[]},{"name":"Rilpivirine","otherNames":[]},{"name":"Darunavir/Cobicistat (FDC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pregnant females (18-26 weeks of gestation)\n* documented HIV-1 infection\n* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study entry\n* Willing to remain on darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine as well as a background regimen, for the duration of the study, including 12 weeks postpartum\n* Able to comply with the protocol requirements and to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with any currently active acquired immune deficiency syndrome (AIDS) defining illness and AIDS-related opportunistic infection\n* Patients using cytokine inhibitors (e.g., thalidomide), anabolic hormones, cytokines (e.g., IL-2, INF), efavirenz, hydroxyurea, oral hypoglycemics, systemic chemotherapy or known teratogenic agent\n* Use of an investigational agent within 90 days\n* Any known fetal anomaly\n* Any current obstetric complication, including multiple gestations and pre-term labor\n* Hepatitis B and/or C virus infection\n* Grade 2 or higher anemia\n* Thyroid disease\n* Uncontrolled Diabetes Mellitus Types I and II, or gestational diabetes, as determined by the investigator","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Predose (Trough) Plasma Concentration (C0h)","description":"C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3608","spread":"2812"},{"groupId":"OG001","value":"491.4","spread":"472.4"},{"groupId":"OG002","value":"2481","spread":"2183"},{"groupId":"OG003","value":"147","spread":"198"},{"groupId":"OG004","value":"281","spread":"193"},{"groupId":"OG005","value":"127","spread":"97.0"},{"groupId":"OG006","value":"2811","spread":"2296"},{"groupId":"OG007","value":"134","spread":"145"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2323","spread":"1140"},{"groupId":"OG001","value":"225.9","spread":"127.5"},{"groupId":"OG002","value":"1793","spread":"964"},{"groupId":"OG003","value":"94.2","spread":"102"},{"groupId":"OG004","value":"439","spread":"212"},{"groupId":"OG005","value":"75.6","spread":"36.2"},{"groupId":"OG006","value":"540","spread":"803"},{"groupId":"OG007","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3280","spread":"1466"},{"groupId":"OG001","value":"236.0","spread":"108.08"},{"groupId":"OG002","value":"1528","spread":"1184"},{"groupId":"OG003","value":"74.6","spread":"90.2"},{"groupId":"OG004","value":"413","spread":"78.2"},{"groupId":"OG005","value":"78.0","spread":"39.1"},{"groupId":"OG006","value":"824","spread":"630"},{"groupId":"OG007","value":"30.1","spread":"51.5"}]}]}]},{"type":"PRIMARY","title":"Minimum Plasma Concentration (Cmin)","description":"The Cmin is the minimum observed plasma concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2851","spread":"2216"},{"groupId":"OG001","value":"264.7","spread":"259.8"},{"groupId":"OG002","value":"1473","spread":"1141"},{"groupId":"OG003","value":"40.5","spread":"31.4"},{"groupId":"OG004","value":"269","spread":"182"},{"groupId":"OG005","value":"84.0","spread":"58.8"},{"groupId":"OG006","value":"1538","spread":"1344"},{"groupId":"OG007","value":"41.4","spread":"49.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1922","spread":"825"},{"groupId":"OG001","value":"141.1","spread":"73.78"},{"groupId":"OG002","value":"1248","spread":"542"},{"groupId":"OG003","value":"32.2","spread":"19.8"},{"groupId":"OG004","value":"383","spread":"210"},{"groupId":"OG005","value":"54.3","spread":"25.8"},{"groupId":"OG006","value":"168","spread":"149"},{"groupId":"OG007","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2661","spread":"1269"},{"groupId":"OG001","value":"148.1","spread":"52.26"},{"groupId":"OG002","value":"1075","spread":"594"},{"groupId":"OG003","value":"28.0","spread":"20.5"},{"groupId":"OG004","value":"349","spread":"103"},{"groupId":"OG005","value":"52.9","spread":"24.4"},{"groupId":"OG006","value":"184","spread":"99.0"},{"groupId":"OG007","value":"NA","spread":"NA"}]}]}]},{"type":"PRIMARY","title":"Maximum Plasma Concentration (Cmax)","description":"The Cmax is the maximum observed plasma concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6659","spread":"2364"},{"groupId":"OG001","value":"1110","spread":"901.2"},{"groupId":"OG002","value":"7310","spread":"1704"},{"groupId":"OG003","value":"742","spread":"335"},{"groupId":"OG004","value":"569","spread":"261"},{"groupId":"OG005","value":"167","spread":"101"},{"groupId":"OG006","value":"7918","spread":"2199"},{"groupId":"OG007","value":"996","spread":"323"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4668","spread":"1097"},{"groupId":"OG001","value":"546.8","spread":"249.4"},{"groupId":"OG002","value":"4964","spread":"1505"},{"groupId":"OG003","value":"439","spread":"241"},{"groupId":"OG004","value":"774","spread":"300"},{"groupId":"OG005","value":"121","spread":"45.9"},{"groupId":"OG006","value":"4340","spread":"1616"},{"groupId":"OG007","value":"571","spread":"350"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5328","spread":"1631"},{"groupId":"OG001","value":"536.1","spread":"210.6"},{"groupId":"OG002","value":"5132","spread":"1198"},{"groupId":"OG003","value":"397","spread":"184"},{"groupId":"OG004","value":"785","spread":"238"},{"groupId":"OG005","value":"123","spread":"47.5"},{"groupId":"OG006","value":"4910","spread":"970"},{"groupId":"OG007","value":"759","spread":"366"}]}]}]},{"type":"PRIMARY","title":"Time to Reach the Maximum Plasma Concentration (Tmax)","description":"The Tmax is defined as actual sampling time to reach maximum observed plasma concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":null},{"groupId":"OG001","value":"5.04","spread":null},{"groupId":"OG002","value":"4.00","spread":null},{"groupId":"OG003","value":"4.18","spread":null},{"groupId":"OG004","value":"4.00","spread":null},{"groupId":"OG005","value":"4.00","spread":null},{"groupId":"OG006","value":"4.00","spread":null},{"groupId":"OG007","value":"4.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":null},{"groupId":"OG001","value":"4.17","spread":null},{"groupId":"OG002","value":"4.00","spread":null},{"groupId":"OG003","value":"5.92","spread":null},{"groupId":"OG004","value":"3.05","spread":null},{"groupId":"OG005","value":"4.00","spread":null},{"groupId":"OG006","value":"4.00","spread":null},{"groupId":"OG007","value":"4.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":null},{"groupId":"OG001","value":"4.07","spread":null},{"groupId":"OG002","value":"3.05","spread":null},{"groupId":"OG003","value":"6.00","spread":null},{"groupId":"OG004","value":"3.00","spread":null},{"groupId":"OG005","value":"4.00","spread":null},{"groupId":"OG006","value":"3.50","spread":null},{"groupId":"OG007","value":"3.50","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours Post-dose (AUC0-12h)","description":"The AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours post dose. The selected arms were based on the dosing frequency (twice daily).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56890","spread":"26340"},{"groupId":"OG001","value":"7406","spread":"6188"},{"groupId":"OG002","value":"5004","spread":"2521"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39370","spread":"9597"},{"groupId":"OG001","value":"3775","spread":"1265"},{"groupId":"OG002","value":"6617","spread":"2766"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45880","spread":"17360"},{"groupId":"OG001","value":"3750","spread":"1336"},{"groupId":"OG002","value":"6846","spread":"1482"}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h)","description":"The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose. The selected arms were based on the dosing frequency (once daily).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92116","spread":"29241"},{"groupId":"OG001","value":"6584","spread":"2861"},{"groupId":"OG002","value":"2714","spread":"1535"},{"groupId":"OG003","value":"99613","spread":"34862"},{"groupId":"OG004","value":"8643","spread":"3187"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62289","spread":"16234"},{"groupId":"OG001","value":"3935","spread":"2063"},{"groupId":"OG002","value":"1792","spread":"711"},{"groupId":"OG003","value":"47293","spread":"19058"},{"groupId":"OG004","value":"3862","spread":"2703"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61112","spread":"13790"},{"groupId":"OG001","value":"3821","spread":"1723"},{"groupId":"OG002","value":"1762","spread":"662"},{"groupId":"OG003","value":"47991","spread":"9879"},{"groupId":"OG004","value":"4736","spread":"2917"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Plasma Viral Load (<) 50 Copies/Milliliter (mL)","description":"Number of participants were assessed with a viral load (VL) lesser than (\\<) 50 HIV-1 RNA copies/ mL over time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Log10 Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Viral Load Value","description":"Mean change from baseline in log 10 HIV-1 RNA VL was assessed up to postpartum (6-12 weeks).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":"0.179"},{"groupId":"OG001","value":"1.88","spread":"0.089"},{"groupId":"OG002","value":"2.06","spread":"0.206"},{"groupId":"OG003","value":"1.84","spread":"0.159"},{"groupId":"OG004","value":"1.77","spread":"0.283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.161"},{"groupId":"OG001","value":"-0.27","spread":"0.145"},{"groupId":"OG002","value":"0.18","spread":"0.182"},{"groupId":"OG003","value":"0.20","spread":"0.172"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.106"},{"groupId":"OG001","value":"-0.16","spread":"0.104"},{"groupId":"OG002","value":"0.16","spread":"0.084"},{"groupId":"OG003","value":"0.16","spread":"0.074"},{"groupId":"OG004","value":"0.1","spread":"0.233"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.107"},{"groupId":"OG001","value":"-0.23","spread":"0.105"},{"groupId":"OG002","value":"0.17","spread":"0.105"},{"groupId":"OG003","value":"0.25","spread":"0.113"},{"groupId":"OG004","value":"0.21","spread":"0.326"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.111"},{"groupId":"OG001","value":"-0.04","spread":"0.146"},{"groupId":"OG002","value":"0.13","spread":"0.168"},{"groupId":"OG003","value":"0.20","spread":"0.273"},{"groupId":"OG004","value":"0.18","spread":"0.304"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.268"},{"groupId":"OG001","value":"0.11","spread":"0.265"},{"groupId":"OG002","value":"0.05","spread":"0.058"},{"groupId":"OG003","value":"0.08","spread":"0.138"},{"groupId":"OG004","value":"0.23","spread":"0.347"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in CD4+ Cell Count","description":"Mean Change From Baseline in CD4+ Cell Count were assessed for immunology testing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"466.3","spread":"49.07"},{"groupId":"OG001","value":"497.9","spread":"64.60"},{"groupId":"OG002","value":"417.47","spread":"80.469"},{"groupId":"OG003","value":"495.79","spread":"79.322"},{"groupId":"OG004","value":"594.17","spread":"108.151"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.8","spread":"23.16"},{"groupId":"OG001","value":"116.3","spread":"62.41"},{"groupId":"OG002","value":"6.25","spread":"26.004"},{"groupId":"OG003","value":"24.00","spread":"56.912"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","spread":"23.31"},{"groupId":"OG001","value":"154.1","spread":"44.08"},{"groupId":"OG002","value":"13.77","spread":"53.225"},{"groupId":"OG003","value":"39.21","spread":"36.496"},{"groupId":"OG004","value":"13.29","spread":"34.445"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":"29.45"},{"groupId":"OG001","value":"274.9","spread":"65.41"},{"groupId":"OG002","value":"77.30","spread":"30.803"},{"groupId":"OG003","value":"89.46","spread":"26.137"},{"groupId":"OG004","value":"72.17","spread":"62.882"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.9","spread":"28.53"},{"groupId":"OG001","value":"186.0","spread":"43.51"},{"groupId":"OG002","value":"115.36","spread":"33.584"},{"groupId":"OG003","value":"139.42","spread":"36.972"},{"groupId":"OG004","value":"163","spread":"37.177"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174.5","spread":"44.98"},{"groupId":"OG001","value":"323.0","spread":"63.99"},{"groupId":"OG002","value":"154.90","spread":"54.131"},{"groupId":"OG003","value":"168.18","spread":"41.345"},{"groupId":"OG004","value":"244.67","spread":"100.74"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Resistance at Virological Failure","description":"Resistance analysis was determined using genotypic and phenotypic analysis at the time of virological failure. For participants with a baseline viral load greater than (\\>) 200 copies/mL, virologic failure was defined as follows: HIV ribonucleic acid (RNA) levels that did not fall by at least 0.5 log 4 weeks after Baseline; viral load \\>1000 copies/mL (at 2 successive visits) by gestational weeks 34-38; or viral load \\>200 copies/mL (at 2 successive visits) after reaching a viral load less than or equal to (\\<=) 200 copies/mL. For participants with a baseline viral load \\<=200 copies/mL, virologic failure was defined as viral load of \\>200 copies/mL (at 2 successive visits) at any point during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Drug in the Cord Plasma and Maternal Plasma Samples Collected at the Time of Delivery","description":"The drug concentrations were evaluated in the cord plasma and maternal plasma samples collected at the time of delivery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348.4","spread":"322.90"},{"groupId":"OG001","value":"17.07","spread":"23.98"},{"groupId":"OG002","value":"228","spread":"302"},{"groupId":"OG003","value":"NA","spread":"NA"},{"groupId":"OG004","value":"147","spread":"61.3"},{"groupId":"OG005","value":"32.8","spread":"16.7"},{"groupId":"OG006","value":"125","spread":"106"},{"groupId":"OG007","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2149","spread":"1140"},{"groupId":"OG001","value":"316.7","spread":"394.4"},{"groupId":"OG002","value":"1663","spread":"1691"},{"groupId":"OG003","value":"154","spread":"274"},{"groupId":"OG004","value":"421","spread":"157"},{"groupId":"OG005","value":"59.0","spread":"34.7"},{"groupId":"OG006","value":"857","spread":"885"},{"groupId":"OG007","value":"74.5","spread":"109"}]}]}]},{"type":"SECONDARY","title":"Number of Infants With Human Immunodeficiency Virus (HIV) Positive Test Result","description":"The infants were evaluated for HIV positive tests using HIV polymerase chain reaction test (PCR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":18},"commonTop":["Nausea","Premature Labour","Anaemia","Vomiting","Vaginitis Bacterial"]}}}